BD (Becton, Dickinson and Company), a global leader in medical technology, has announced the initiation of the first pharma-sponsored clinical trial utilizing the BD Libertas™ Wearable Injector for subcutaneous delivery of complex biologic drugs. This trial marks a significant step towards enhancing patient care by potentially converting infused medications that require hospital visits to more convenient self-injection options at home. The BD Libertas™ Wearable Injector, which has been validated through over 50 pre-clinical and clinical studies conducted by BD, offers a fully mechanical, patient-ready design with a straightforward "peel, stick and click" mechanism. The results of this trial have not yet been presented. For further information on the BD Libertas™ Wearable Injector and its capabilities, interested parties are directed to visit BD's official website.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。